FDA commish: First Amendment DTC defense airtight

Share this article:
FDA commissioner Andrew von Eschenbach issued a staunch First Amendment defense of DTC advertising at last week’s Center for Medicine in the Public Interest conference in Washington, DC. Asked his view on the controversy over DTC and the prospects of legislative tinkering with advertising regulation, von Eschenbach said: “As with any particular entity, whether an organization or individual, there is a right to free speech and an ability under the Constitution to free expression. We need to make sure the content is factual and accurate. FDA has role in making sure the public is continuing to get correct information.”
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...